Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
79
days
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
Authors
Bora Lee; Hyeon Ji Park; Byeong Min Yoo; Hangil Kim; Arim Seo; Youngeun Hong; Yo-Seob Lee; Donghoon Yeom; Yong-Gyu Son; Jaehyun Eom; Daehae Song; Byungje Sung; Jinhyung Ahn; Junyoung Kim; Weon-Kyoo You; Sang Hoon Lee; Jinwon JungShow moreShow less
Affiliations
1. https://ror.org/01e0hcx30ABL Bio Inc., Seoul, Republic of Korea.Show moreShow less
86
days
An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Authors
Christopher M. Carosino; Devra J. Olson; Rebecca C. Mazahreh; David J. Ortiz; Steve Duniho; Eliana Moskovitz; Marlena Gray; Renee F. Hein; Nicolas H. Garcia; Hamidreza Ardalani; Lauren Farr; Tianyang Yan; Maddy Burcher; Iliyana Mikell; Matthew R. Levengood; Sharsti Sandall; Joseph D. DekkerShow moreShow less
Affiliations
1. Pfizer, Inc., Bothell, Washington.Show moreShow less
256
days
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers
Authors
Karine Smans; Thomas Nesspor; Sabine De Breucker; Erika van Heerde; Annemie Valckx; Nele Van Slycken; Katrin Sproesser; Bethany Mattson Cypert; Kathryn Packman; Gerald Chu; Jamie Fisher; Nicholas Mazzanti; Ted Petley; Winnie Chan; Brian Del Rosario; Tun Liu; Stuart Ember; Paul L. Shaffer; Jacalyn S. Clawson; Joshua M. Bauml; Sheri Moores; Sylvie Laquerre; Paul R. GavineShow moreShow less
Affiliations
1. Oncology, Johnson & Johnson, Beerse, Belgium.; 2. Therapeutics Discovery, https://ror.org/03qd7mz70Johnson & Johnson, Springhouse, Pennsylvania.; 3. Oncology, https://ror.org/03qd7mz70Johnson & Johnson, Springhouse, Pennsylvania.; 4. Oncology, https://ror.org/03qd7mz70Johnson & Johnson, Cambridge, Massachusetts.Show moreShow less
234
days
Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Authors
Faith Fowler; Jessica Gajda; Amirhossein Mafi; Aileen Kelly; Cynthia L. Jeffries; Phuong Le; Lei Shi; Mariam George; Nathaniel Elsen; Alla V. Korepanova; Sarah M. Zerbs; Orville A. Pemberton; Xiangdong Xu; Nathan Gesmundo; Wei Qiu; Fei Han; Henry Tang; Sanjay C. Panchal; Michael Dart; Jonathan Hickson; Chaohong Sun; Yunsong Tong; Ari J. FirestoneShow moreShow less
Affiliations
1. Calico Life Sciences LLC, South San Francisco, California.; 2. https://ror.org/02g5p4n58AbbVie (United States), North Chicago, Illinois.Show moreShow less
174
days
NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors
Authors
Theodore T. Nguyen; Nitesh K. Nandwana; Yellamelli V.V. Srikanth; Tetyana Bagnyukova; Oleksandra Chkhalo; Kathy Q. Cai; Julia Lamperelli; Shabnam Pirestani; Manish Kumar Mehra; Barbara A. Burtness; Hossein Borghaei; Ravikumar Akunuri; Joel Cassel; Lily Lu; Joseph M. Salvino; Erica A. GolemisShow moreShow less
Affiliations
1. https://ror.org/0567t7073Fox Chase Cancer Center, Philadelphia, Pennsylvania.; 2. Drexel University College of Medicine, Philadelphia, Pennsylvania.; 3. Medicinal Chemistry and Molecular and Cellular Oncogenesis Program, https://ror.org/04wncat98The Wistar Institute, Philadelphia, Pennsylvania.; 4. Pharmaceutical Faculty, Bogomolets National Medical University, Kyiv, Ukraine.; 5. Section of Medical Oncology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.; 6. Molecular Screening Shared Resource, https://ror.org/04wncat98The Wistar Institute, Philadelphia, Pennsylvania.; 7. Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Philadelphia, Pennsylvania.Show moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days